Impact of early blood purification on inflammatory markers and prognosis in septic shock patients with acute kidney injury
10.3760/cma.j.issn.1671-0282.2025.05.016
- VernacularTitle:早期血液净化对感染性休克肾损伤患者炎症指标及预后的影响
- Author:
Lingchen KONG
1
;
Guosheng CHENG
;
Peng WU
;
Haifei LONG
;
Min YANG
;
Wenhong PENG
Author Information
1. 临沂市中心医院重症医学科，临沂 276400
- Keywords:
Septic shock;
Acute kidney injury;
Inflammatory markers;
Blood purification
- From:
Chinese Journal of Emergency Medicine
2025;34(5):716-722
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aimed to evaluate the therapeutic efficacy of early bedside plasma adsorption (PA) combined with pulse high-volume hemofiltration (PHVHF) in patients with septic shock and acute kidney injury (AKI).Methods:A prospective randomized controlled trial was conducted, enrolling septic shock patients with AKI admitted to the intensive care unit of Linyi Central Hospital between January 2022 and January 2024. Participants were randomly assigned to either the Continuous Veno-Venous Hemofiltration (CVVH) group or the integrated treatment group (PHVHF+PA). Both groups received standard care following the 2021 Surviving Sepsis Campaign guidelines. Both groups received standard treatment according to the 2021 Surviving Sepsis Campaign guidelines. The CVVH group received standard CVVH, while the integrated therapy group underwent PHVHF [substitution fluid rate: 85 mL/(kg·h)] combined with PA. Organ function indices, hemodynamic parameters, inflammatory markers, critical illness scores before treatment, at 24 h and 72 h after treatment, and 28-day survival outcomes were monitored. Categorical data were analyzed using the χ2 test, continuous variables were compared with independent samples t-test, repeated-measures data were analyzed by ANOVA, and 28-day survival was evaluated using Kaplan-Meier curves.Results:A total of 56 septic shock patients with AKI were enrolled and randomly divided into CVVH group ( n=27) and integrated therapy group ( n=29). The baseline characteristics including age, gender, and body mass index were comparable between groups (all P>0.05). No significant differences in organ function or hemodynamic parameters were observed before treatment (all P>0.05). At 24 h post-treatment, both groups showed significant improvements in serum creatinine (Scr), mean arterial pressure, heart rate, and lactate levels (all P<0.05), with reduced norepinephrine requirements ( P<0.05). The integrated treatment group demonstrated significant improvements in oxygenation index (PaO 2/FiO 2), total bilirubin, APACHEⅡ and SOFA scores (all P<0.05). By 72 h, the integrated therapy group exhibited significantly higher PaO 2/FiO 2, platelet counts, and MAP, alongside lower total bilirubin, Scr, HR, norepinephrine dosage, and Lac (all P<0.05). Both groups showed reductions in APACHEⅡ, SOFA scores, procalcitonin, C-reactive protein, TNF-α, IL-6, and IL-10 (all P<0.05). The integrated treatment group had shorter ICU stays [(8.9±2.8) d vs. (11.2±3.6) d, P=0.005), and higher 28-day renal function recovery rates [15(51.7%) vs. 8(29.6%), P=0.033] than CVVH group, though no significant differences were observed in 7-day or 28-day survival rates between groups (both P>0.05). Conclusions:Compared to CVVH, the combined therapy of PHVHF and PA demonstrates superior efficacy in eliminating inflammatory mediators and enhancing organ function. However, this combination does not significantly influence 28-day survival outcomes in patients.
